Zacks Investment Research upgraded shares of Helius Medical Technologies (NASDAQ:HSDT – Get Rating) from a hold rating to a buy rating in a report published on Tuesday morning, Zacks.com reports. The brokerage currently has $1.75 target price on the stock. According to Zacks, “Helius Medical Technologies Inc. is a specialty medical device company. It is […]
Second Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate the impact of subjects’ adherence to PoNS® therapy for gait. | May 17, 2022
Helius Medical Technologies, Inc. (NASDAQ:HSDT – Get Rating) was the target of a significant decrease in short interest during the month of April. As of April 30th, there was short interest totalling 14,300 shares, a decrease of 31.9% from the April 15th total of 21,000 shares. Based on an average daily volume of 16,700 shares, […]
Helius Medical Technologies, Inc. (NASDAQ:NASDAQ:HSDT) Q1 2022 Earnings Conference Call May 12, 2022 9:00 AM ET Company Participants Judy DiClemente – In-Site Communications, Inc.
NEWTOWN, Pa., March 14, 2022 (GLOBE NEWSWIRE) Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused.